PDX Pharmaceuticals Secures Additional Investment from the Kuni Foundation to Advance New Cancer-Fighting Precision Therapies

PDX Pharmaceuticals received a second round of Series A funding in the amount of $2 million from the Kuni Foundation.

See the press release here

PDX’s CEO and Founder, Wassana Yantasee, PhD commented: “My team and I are excited to embark on this next phase of our clinical development initiatives with the intention of vastly improving the efficacy of currently approved cancer therapies, overcoming drug resistance to targeted therapies, and triggering antitumor immunity in cancer patients.  We are truly fortunate to have the strategic and financial backing of the Kuni Foundation, contributing invaluable leadership and financial support to PDX as we continue to execute our mission of developing and commercializing next-generation, highly-effective therapies in oncology.”

“This next round of investment underscores our excitement regarding the progress Wassana and her team have made and our confidence in the potential of this approach,” said Greg Goodwin, Board Chair of the Kuni Foundation. “This is an example of the kind of innovative thinking that will lead to better outcomes for cancer patients, while also improving accessibility and affordability.”